10x Genomics

10x Genomics
10x Genomics · Public domain · source
Name	10x Genomics
Type	Public
Industry	Biotechnology
Founded	2012

10x Genomics is a biotechnology company that develops genomic analysis platforms used in research across molecular biology, oncology, neurology, and immunology. The company builds instruments and consumables that enable high-throughput single-cell and spatial profiling, integrating microfluidics, sequencing, and computational workflows. Its technologies are adopted by academic institutions, pharmaceutical companies, and government laboratories for discovery and translational research.

History

The company was founded in 2012 by scientists and entrepreneurs influenced by work at Stanford University, University of California, Berkeley, and collaborations with researchers from Broad Institute, Massachusetts Institute of Technology, and Harvard Medical School. Early funding rounds involved investors associated with Sequoia Capital, Andreessen Horowitz, and First Round Capital, while advisory input came from researchers at Cold Spring Harbor Laboratory and Salk Institute. Product launches in the 2010s coincided with advances in single-cell sequencing seen in publications from Rosalind Franklin University and laboratories led by investigators associated with NIH intramural programs and the Wellcome Trust. The company transitioned to a public company via an initial public offering influenced by market activity in biotechnology sectors including firms like Illumina, Pacific Biosciences, and Thermo Fisher Scientific.

Products and Technologies

Commercial offerings include integrated systems combining microfluidic controllers, barcoded beads, and library preparation kits linked to sequencing platforms from Illumina and computational pipelines used in core facilities at institutions such as Scripps Research, Johns Hopkins University, and University of Chicago. Landmark technologies are designed for single-cell RNA sequencing and linked-read genomics that build on earlier methods reported by groups at University of Washington and University of Oxford. Spatial transcriptomics products align with efforts by teams associated with Karolinska Institute, Max Planck Institute, and Institut Pasteur. Proprietary chemistry and software integrate with analysis tools used by groups at EMBL-EBI, European Molecular Biology Laboratory, and labs collaborating with Cancer Research UK centers.

Applications

The platforms are used to dissect cellular heterogeneity in studies originating from cancer centers like Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute, neuroscience investigations at MIT McGovern Institute, and immunology programs at Fred Hutchinson Cancer Research Center. Pharmaceutical and biotechnology firms including Roche, Novartis, Pfizer, and Gilead Sciences employ the technologies in target discovery and biomarker development. Public health and infectious disease research drawing on datasets from Centers for Disease Control and Prevention and consortiums such as the Human Cell Atlas use the systems for profiling host responses in studies influenced by work at Pasteur Institute and Johns Hopkins Bloomberg School of Public Health.

Business and Financials

The company’s market activity interacts with capital markets where peers like Illumina and Agilent Technologies set competitive benchmarks; financial reporting engages analysts from firms such as Goldman Sachs, Morgan Stanley, and JP Morgan Chase. Revenue streams derive from instrument sales, consumables, and licensing, with customer bases including academic institutions like Stanford Medicine and corporate partners such as Bristol Myers Squibb. Strategic corporate actions have been analyzed in the context of mergers and acquisitions trends featuring companies like Thermo Fisher Scientific and private investors like BlackRock; governance involves boards with members experienced at Genentech and Amgen.

Research and Collaborations

Academic collaborations involve laboratories at Harvard University, Yale University, Columbia University, and international centers including Imperial College London and University College London. Large-scale initiatives incorporate datasets and standardization efforts aligned with the Human Cell Atlas consortium and partnerships with national research agencies like NIH and funders such as the Wellcome Trust. Industry collaborations have included projects with pharmaceutical companies like AstraZeneca and diagnostics programs developed alongside clinical networks at Mayo Clinic and Cleveland Clinic.

Controversies and Criticism

Controversies touching the company have centered on intellectual property disputes similar to disputes previously seen among sequencing companies including Illumina and Pacific Biosciences, and debates over pricing and access reminiscent of issues raised around Thermo Fisher Scientific sales practices. Academic and industry stakeholders at institutions such as University of California, San Francisco and University of Pennsylvania have engaged in discussions about reproducibility, data sharing policies linked to repositories like GenBank and European Nucleotide Archive, and competitive dynamics in procurement for core facilities at universities including Cornell University and Princeton University.

Category:Biotechnology companies